iRhythm Technologies, Inc. — 2017 Form 10-K
Period: Fiscal year ended December 31, 2017; filed March 1, 2018. This is an annual report, not a standalone quarterly filing. The filing identifies the registrant as iRhythm Technologies, Inc. (NASDAQ: IRTC), rather than “Irhythm Holdings, Inc.”
Business context
iRhythm is a commercial-stage digital healthcare company whose principal business is the Zio ambulatory ECG monitoring service: a wearable sensor, cloud-based analysis, technician review, and physician report. Revenue is substantially from Zio services in the United States. The company reported more than one million patients served and approximately 290 million U.S. individuals covered by government or private reimbursement policies at year-end. Zio AT, cleared by the FDA in June 2017 to provide wireless transmission of critical events, was in limited release.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $98.5 million | $64.1 million |
| Gross profit / margin | $70.8 million / 72% | $43.2 million / 67% |
| Operating expenses | $98.1 million | $58.8 million |
| Operating loss | $27.3 million | $15.6 million |
| Net loss | $29.4 million | $20.9 million |
| Cash used in operating activities | $14.9 million | $16.7 million |
- Revenue grew 54%, primarily from higher service volume, expanded reimbursement coverage and contracts, physician adoption, and sales-force growth. Gross margin improved five percentage points, attributed to manufacturing efficiencies, lower labor per device, fixed-cost absorption, and customer mix.
- R&D expense rose 87% to $13.3 million; selling, general and administrative expense rose 64% to $84.7 million. Stock-based compensation increased to $10.1 million from $1.9 million.
- At year-end, cash and cash equivalents were $8.7 million; short- and long-term investments totaled $96.7 million. Working capital was $98.7 million and total assets were $133.1 million.
- Debt was $34.0 million, including $32.5 million under the Pharmakon loan and a $1.5 million CHCF note; no amount was drawn on the SVB revolving line. The Pharmakon loan carries a 9.5% fixed rate and matures in December 2021. The company reported compliance with debt covenants.
- Capital expenditures were $3.6 million. Financing activities provided $6.5 million, primarily from employee equity plans; investing activities used $34.6 million, largely reflecting investment purchases net of maturities.
Quarterly comparison and material changes
In the fourth quarter of 2017, revenue was $28.2 million versus $18.7 million in Q4 2016; gross profit was $20.5 million versus $12.9 million. Net loss widened to $11.1 million from $6.3 million. For the full year, the operating loss widened by $11.7 million and net loss increased by $8.5 million, as operating expenses grew faster than revenue. Cash used in operations improved by $1.7 million year over year.
Outlook, commentary, and risks
- Management expects continued investment in sales capacity, reimbursement contracting, product development, and clinical evidence. It expects cost of revenue to rise with volume and aims to reduce unit costs through purchasing scale, algorithm improvements, and workflow automation. The filing does not provide numerical revenue or earnings guidance.
- Management expects continued losses and states that profitability is not assured. Key dependencies include physician adoption, reimbursement coverage and rates, collections, and successful commercialization of new products. Approximately 82% of 2017 revenue came through third-party payors; CMS represented approximately 28%.
- Significant disclosed risks include reimbursement reductions or denials, collection uncertainty and bad debt, competition, reliance on a single product and certain single-source components, scaling manufacturing and analysis capacity, medical-device regulation, data privacy and cybersecurity, and the company’s history of losses.
- Revenue recognition involves estimates for reimbursement and contractual allowances. The 2018 adoption of Topic 606 was expected to have no material cumulative impact, but would change presentation of patient-responsibility bad debt and could affect timing of some non-contracted payor revenue.
- The 2017 tax-law changes resulted in provisional tax accounting; the company recorded no income-tax provision or benefit and maintained a full valuation allowance against deferred tax assets. The filing reports no material litigation. Management and PwC concluded internal control over financial reporting was effective as of year-end.
Important facts for investors to verify
- Whether revenue growth, reimbursement coverage, and contracted payor mix continue, and how much reported revenue converts to cash.
- Accounts-receivable quality, allowance levels, and collection trends, given the increase in receivables and bad-debt and contractual-allowance provisions.
- Whether gross-margin gains persist while the company expands sales, operations, and Zio AT commercialization.
- Debt-service capacity, covenant headroom, liquidity requirements, and the timing of scheduled repayments.
- Progress on Zio AT adoption, clinical studies, and expanded indications, alongside regulatory, competitive, supply-chain, and data-security risks.